Page last updated: 2024-09-05

darunavir and jtk-303

darunavir has been researched along with jtk-303 in 13 studies

Compound Research Comparison

Studies
(darunavir)
Trials
(darunavir)
Recent Studies (post-2010)
(darunavir)
Studies
(jtk-303)
Trials
(jtk-303)
Recent Studies (post-2010) (jtk-303)
1,14822478036256293

Protein Interaction Comparison

ProteinTaxonomydarunavir (IC50)jtk-303 (IC50)
Integrase Human immunodeficiency virus 10.911

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's9 (69.23)24.3611
2020's3 (23.08)2.80

Authors

AuthorsStudies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Enejosa, J; Hinkle, J; Kearney, BP; Mack, R; Mathias, AA; Piliero, PJ; Sekar, V; Shen, G; Tomaka, F1
Berger, DS; Cheng, AK; Chuck, SL; Enejosa, JV; Kearney, BP; Lampiris, H; Zhong, L; Zolopa, AR1
Lacombe, K; Surgers, L1
Gauthier, TP; Schafer, JJ; Sherman, EM; Unger, NR; Worley, MV1
Balogh, A; Iakoubov, R; Kern, KE; Noe, S; Schmid, RM; Schwerdtfeger, C; Spinner, CD; Von Werder, A; Wolf, E; Zink, A1
Benmarzouk-Hidalgo, OJ; Espinosa, N; Fernandez-Magdaleno, T; Gutierrez-Valencia, A; Llaves, S; Lopez-Cortes, LF; Viciana, P1
Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J1
Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B1
Álvarez, H; Llibre, JM; Yzusqui, M1
Cabot, JF; Denault, JS; Langlois, H; Marcotte, S; Sheehan, NL1
Amador, C; de Zárraga, MA; Díez Martínez, M; Górgolas, M; Jarrín, I; Moreno, C; Navarro, M; Pérez-Elías, MJ; Pérez-Martínez, L; Ruiz-Algueró, M; Suárez-García, I; Viciana, P1
Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R1

Reviews

4 review(s) available for darunavir and jtk-303

ArticleYear
Hepatoxicity of new antiretrovirals: a systematic review.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2

    Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles

2013
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
    Clinical therapeutics, 2015, Sep-01, Volume: 37, Issue:9

    Topics: Anti-HIV Agents; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Quinolones

2015
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:11

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir

2017
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
    AIDS reviews, 2018, Volume: 20, Issue:3

    Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load

2018

Trials

4 trial(s) available for darunavir and jtk-303

ArticleYear
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
    Journal of acquired immune deficiency syndromes (1999), 2008, Oct-01, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pyridines; Pyrones; Quinolones; Ritonavir; Sulfonamides

2008
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
    The Journal of infectious diseases, 2010, Mar-15, Volume: 201, Issue:6

    Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pyridines; Pyrones; Quinolones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Young Adult

2010
Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study.
    Antiviral therapy, 2016, Volume: 21, Issue:7

    Topics: Adult; Darunavir; Emtricitabine; Healthy Volunteers; Humans; Insulin Resistance; Prospective Studies; Quinolones; Tenofovir; Triglycerides

2016
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    AIDS research and therapy, 2017, Nov-02, Volume: 14, Issue:1

    Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load

2017

Other Studies

5 other study(ies) available for darunavir and jtk-303

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
    The Journal of antimicrobial chemotherapy, 2017, 03-01, Volume: 72, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Young Adult

2017
Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
    Antiviral therapy, 2019, Volume: 24, Issue:1

    Topics: Anti-Retroviral Agents; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Quinolones

2019
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
    AIDS research and therapy, 2020, 07-20, Volume: 17, Issue:1

    Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Spain; Tenofovir; Treatment Outcome; Viral Load

2020
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States

2022